434 related articles for article (PubMed ID: 38087370)
1. Targeting the myeloid microenvironment in neuroblastoma.
Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.
De Sanctis F; Adamo A; Canè S; Ugel S
Semin Immunopathol; 2023 Mar; 45(2):163-186. PubMed ID: 36161514
[TBL] [Abstract][Full Text] [Related]
3. "Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.
Liu KX; Joshi S
Front Immunol; 2020; 11():1947. PubMed ID: 32983125
[TBL] [Abstract][Full Text] [Related]
4. Innate myeloid cells in the tumor microenvironment.
Duhan V; Smyth MJ
Curr Opin Immunol; 2021 Apr; 69():18-28. PubMed ID: 33588308
[TBL] [Abstract][Full Text] [Related]
5. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
[TBL] [Abstract][Full Text] [Related]
6. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
Zhao Y; Du J; Shen X
Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
[TBL] [Abstract][Full Text] [Related]
9. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
[TBL] [Abstract][Full Text] [Related]
10. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
11. Neutrophils in cancer.
Treffers LW; Hiemstra IH; Kuijpers TW; van den Berg TK; Matlung HL
Immunol Rev; 2016 Sep; 273(1):312-28. PubMed ID: 27558343
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S; Sharabi A
Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy.
Wang Y; Johnson KCC; Gatti-Mays ME; Li Z
J Hematol Oncol; 2022 Aug; 15(1):118. PubMed ID: 36031601
[TBL] [Abstract][Full Text] [Related]
14. Developmental pathways of myeloid-derived suppressor cells in neoplasia.
Abrams SI
Cell Immunol; 2021 Feb; 360():104261. PubMed ID: 33373817
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
16. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
17. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
20. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
